International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 662-669 , 1 July 2010

Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402

  • Meihua Wang, Ph.D.

      Affiliations

    • American College of Radiology, Philadelphia, PA
    • Corresponding Author InformationReprint requests to: Meihua Wang, Ph.D., RTOG Senior Biostatistician, American College of Radiology, 1818 Market Street, 16th Floor, Philadelphia, PA, 19103. Tel: (215) 574-3207; Fax: (215) 928-0153
    • ,
  • Gregory Cairncross, M.D.

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Edward Shaw, M.D.

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Robert Jenkins, Ph.D.

      Affiliations

    • Mayo Clinic, Rochester, MN
    • ,
  • Bernd Scheithauer, M.D.

      Affiliations

    • Mayo Clinic, Rochester, MN
    • ,
  • David Brachman, M.D.

      Affiliations

    • Foundation for Cancer Research, Phoenix, AZ
    • ,
  • Jan Buckner, M.D.

      Affiliations

    • Mayo Clinic, Rochester, MN
    • ,
  • Karen Fink, M.D., Ph.D.

      Affiliations

    • Baylor University Medical Center, Dallas, TX
    • ,
  • Luis Souhami, M.D.

      Affiliations

    • McGill University, Montreal, PQ, Canada
    • ,
  • Normand Laperriere, M.D.

      Affiliations

    • University of Toronto, Toronto, ON, Canada
    • ,
  • Minesh Mehta, M.D.

      Affiliations

    • University of Wisconsin, Madison, WI
    • ,
  • Walter Curran, M.D.

      Affiliations

    • Emory University Medical Center, Atlanta, GA
    • ,
  • Radiation Therapy Oncology Group (RTOG)
    • ,
  • North Central Cancer Treatment Group (NCCTG)
    • ,
  • Southwest Oncology Group (SWOG)
    • ,
  • National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
    • ,
  • Eastern Cooperative Oncology Group (ECOG)

Received 13 April 2009 ,Revised 1 June 2009 ,Accepted 1 June 2009.

References 

  1. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery. 1992;31:78–82
  2. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiotherapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–2714
  3. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–18
  4. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  5. Aaronson NK, Bakker W, Stewart AL, et al. Multidimensional approach to the measurement of quality of life in lung cancer clinical trials. In:  Aaronson NK,  Beckmann J editor. The quality of life of cancer patients. New York: Raven Press; 1987;p. 63–82
  6. Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparison with Karnofsky performance scores. J neuro-Oncol. 1992;14:243–253
  7. Fairclough D. Design and analysis of quality of life studies in clinical trials. Boca Raton, FL: Chapman & Hall/CRC; 2003;
  8. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988;
  9. Sloan J, Cella D, Hays R. Clinical significance of patient-reported questionnaire data: Another step toward consensus. J Clin Epidemiol. 2005;58:1217–1219
  10. Vonesh EF, Greene T, Schluchter MD. Shared parameter models for the joint analysis of longitudinal data and event times. Stat Med. 2006;25:143–163
  11. Zeng D, Cai J. Simultaneous modeling of quality of life and survival time. Lifetime Data Anal. 2005;11:151–174
  12. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000;1:465–480
  13. Guo X, Carlin B. Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Stat. 2004;58:16–24
  14. Cairncross G, Wang M, Shaw E, et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): The perspective of longer follow-up [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(Suppl 1):S206
  15. Klein J, Moeschberger M. Survival analysis: techniques for censored and truncated data. New York: Springer; 2003;
  16. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol. 1990;28:818–822
  17. Lezak MD, Howieson DB, Loring DW, et al. Neuropsychological assessment. 4th ed.. Oxford: Oxford University Press; 2004;
  18. Meyers C, Hess K, Yung W, et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18:646–650
  19. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc. 1992;40:922–935
  20. Salmon D, Thal L, Butters N, et al. Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examinations. Neurology. 1990;40:1225
  21. Galasko D, Klauber MR, Hofstetter CR, et al. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Arch Neurol. 1990;47:49–52
  22. Wade DT. Measurement in neurological rehabilitation. Oxford: Oxford University Press; 1992;
  23. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002;20:3445–3453
  24. Mehta MP, Rodrigus P, Terhaard CHJ, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529–2536
  25. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol. 2004;22:157–165
  26. Bosma I, Vos MJ, Heimans JJ, et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol. 2007;9:53–62
  27. Li J, Bentzen SM, Li J, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71:64–70
  28. Taylor BV, Buckner JC, Cascino TL, et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol. 1998;16:2195–2201
  29. Corn BW, Moughan J, Knisely JPS, et al. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. Int J Radiat Oncol Biol Phys. 2008;71:71–78
  30. Murray KJ, Scott C, Zachariah B, et al. Importance of the mini-mental status examination in the treatment of patients with brain metastases: A report from the Radiation Therapy Oncology Group protocol 91-04. Int J Radiat Oncol Biol Phys. 2000;48:59–64
  31. Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427–5433
  32. Brown PD, Buckner JC, O'Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J Clin Oncol. 2003;21:2519–2524

 Conflict of interest: none.

PII: S0360-3016(09)00833-5

doi: 10.1016/j.ijrobp.2009.06.004

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 662-669 , 1 July 2010

Article Tools

* Image Usage & Resolution